T he immune system, normally characterized by specificity, enormous repertoire, efficiency, and fine-tuned regulation, does not always function optimally and beneficially to the host. Three examples are allergy, autoimmunity, and failure to protect against syngenic tumors. In the first case, the immune system reacts far too strongly. In the two latter cases, the system reacts inappropriately and insufficiently, respectively, against selfcomponents (1, 2). Immune responses are initiated by the interaction between processed Ag presented by APC and the TCR complex on the surface of Th cells. Upon activation, these latter cells produce cytokines, which help the development of Ag-specific B cells and CTLs from precursor cells. The TCR molecule is a heterodimer of TCR␣ and TCR␤ chains, the genes of which rearrange randomly in differentiating T cells. Therefore, developing T cells may express one of multiple combinations of TCR␣ and ␤-chains and some of these combinations may be autoreactive (3, 4) . Autoimmune reactions are normally avoided by negative selection of autoreactive immune cells (5, 6) . Negative selection in the thymus is dependent on the avidity of the TCR for its ligand (formed as a function of the avidity of the MHC-encoded class I and class II molecules for self-peptides) as well as on the interaction of several coreceptors on both APC and Th cells (7) . Thus, T cells with high-avidity TCR specific for TCR peptides associated with class I or class II proteins are assumed to be deleted.
However, immune cells with reactivity against variable and constant regions of self-TCR are present in the immunological repertoire of normal mice (8 -16) . B cell responses are directed against conformational TCR epitopes, producing anti-clonotypic Abs (8 -12) . In contrast, CD4
ϩ and CD8 ϩ T cell responses are specific for TCR peptides associated with MHC class II and class I molecules, respectively (13) (14) (15) (16) . Nascent TCR chains may either be processed for MHC class I presentation within the T cell itself (17) or TCR proteins may somehow be internalized, processed, and associated with MHC class I or class II molecules by professional APC (18) .
TCR-specific CD4 ϩ T cells have been described as playing an important regulatory role in autoimmunity (13, 15, 16, 19, 20) . CD8 ϩ T cells have also been suggested to play such a role, but in these studies either the function, specificity, or MHC restriction of the CD8 ϩ cells were not reported (14, 21, 22) . We have found previously 1) that TCR-specific CD8 ϩ T cells play a significant biological role in the regulation of experimental autoimmune encephalomyelitis (EAE) 3 (23, 24) and 2) that mice vaccinated with mitomycin C (Mito-C)-treated T lymphoma cells were resistant to new challenge with the same T lymphoma cells and that this immunity may be TCR specific (24, 25) . In the present study, we have tried to elucidate the different parameters of an immune response to TCR chains: 1) the lymphocytes involved in the initiation and effector phases of the response, 2) the mechanism of the effector phase, and 3) the fine specificity and MHC restriction of the effector cells. The protective immune response of C57BL/6 mice to the syngeneic L12R4 T lymphoma cells was used as a model system. Our data show that TCR-V␤ peptides may be presented by L12R4 T lymphoma cells and that vaccination against the TCR-V␤12 region of the L12R4 TCR␣␤ heterodimer protects against L12R4 cells, but not against TCR␤-negative L12R4 cells, TCR-V␤2-expressing L12R4 cells, or C57BL/6 T lymphoma cells with other TCR␣␤ heterodimers (15). Furthermore, IFN-␥-and TNF-␣-producing CD8 ϩ T cells with reactivity to TCR-V␤ regions play an important role in protection against L12R4 T cell lymphomas. In contrast, CD4
ϩ T cells appear important in certain stages of the immune response to L12R4 cells, but not for direct effector function against the T lymphoma cells.
Materials and Methods
Mice, immunization, and cell transfer C57BL/6 (B6), BALB/c, and B6-IFN-␥ Ϫ/Ϫ mice were bred in our in-house specific pathogen-free animal facility from stocks originally obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were immunized i.p. with 10 ϫ 10 6 Mito-C-treated T lymphoma cells three times at weekly intervals (25) (H-2 d ) were used as described previously (24, 25) . They were grown in vivo by passage of 10 6 live tumor cells every 10 -14 days or in vitro in 8% FCS/RPMI 1640 (FCS/R) medium. X6310 cells produce mouse IL-2 in 8% FCS/R (26); these cells were generously provided by Dr. F. Melchors (Basel Institute for Immunology, Basel, Switzerland). L12R4 cells were mutagenized as described previously for human Jurkat T cells (27) . Surface TCR/CD3-negative L12R4 cells were immunoselected, cloned at limiting dilution, and one clone (P3.3) was selected (see Results). P3.3 cells were transfected with either V␤2 or V␤12 DNA (27) and V␤2 ϩ or V␤12
ϩ transfectant cells were selected with specific mAb using flow cytometry. The V␤2 ϩ P3.3 cells, called T142.4 cells, were used in the present experiments (see Fig. 3 ). Both P3.3 and T142.4 cells grow in B6 mice as L12R4 cells.
Reagents
The 2C11 anti-CD3⑀, H57 anti-TCR.C␤, anti-V␤2, H129 anti-CD4, H58.55 anti-CD8, and H140.61 anti-Thy1 mAb were produced in vitro from hybridoma cells obtained from Drs. J. Bluestone, R. Kubo, B. Malissen, and M. Pierres, respectively (28) . Anti-TCR.C␣, anti-K b , anti-D b , and anti-V␤12 mAb were obtained from BD Pharmingen (San Diego, CA). M1/42 rat anti-mouse MHC class I mAb and Ox3 anti-IA b mAb were provided by American Type Culture Collection (Manassas, VA) and Dr. A. Williams (Oxford, U.K.), respectively. MTT was purchased from SigmaAldrich (St. Louis, MO). Thirty microliters of a 5-mg/ml solution in Dulbecco's PBS was added per well.
IL-4, IFN-␥, and TNF-␣ contents in T cell supernatants (harvested on days 1, 2, or 3) were determined using BD Pharmingen ELISA kits 555232, 555138, and 558874, respectively, by means of the protocol indicated by the manufacturer. IL-2 activity was measured by growth of CTLL-2 cells (28) .
The p67-78 peptide was produced and purified by Neosystems (Strasbourg, France). It was Ͼ95% pure.
T cell lines and cell separations
T and B cell separations were performed using either anti-Thy1 mAb or anti-mouse Ig (MIg) Ab-coated magnetic beads from Miltenyi Biotec (Auburn, CA). CD4 ϩ or CD8 ϩ T cells were obtained from cells first treated with anti-MIg beads, and then column nonadhering cells were incubated with either anti-CD4 mAb or anti-CD8 mAb beads. In different experiments, CD4
ϩ and CD8 ϩ T cells were prepared by both positive and negative selection. In some cases, T cells were purified on MIg anti-MIg columns as before (28) .
T lymphoma cells used for immunization or for stimulator cells in vitro were treated with 100 g/ml of Mito-C (Sigma-Aldrich) at 37°C for 1 h followed by three washings. Spleen cells were treated with 50 g/ml Mito-C at 37°C for 30 min, and effector T cells were treated with 5-50 g/ml Mito-C at 37°C for 30 min. M cells only. The percentage of T cell subsets as well as the content of anti-TCR Abs in antiserums from vaccinated mice were determined by flow cytometry using fluorescent F(abЈ) 2 of rabbit anti-MIg Abs as described previously (27, 28) . 
L12R4 cell growth inhibition assay

T cell proliferation and cytotoxicity assays
Proliferation of effector T cells against different T lymphoma cells and splenic APC was measured by [ 3 H]thymidine incorporation (the radioactivity was present for 18 h between days 4 and 5), and the 51 Cr release assay was performed as described previously (28, 29) cDNA cloning and sequence analysis Total RNA was prepared from 10 7 L12R4 cells by means of the RNA PLUS method (Bioprobe Systems, France); cDNA production, PCR analysis, cloning of PCR products with the pCTTM II vector kit (Invitrogen Life Technologies, San Diego, CA), and nucleotide sequencing using the T7 kit (Pharmacia, Uppsala, Sweden) were all performed as described in detail elsewhere (27) .
Immunoprecipitations
L12R4 T cells, variant cells, and transfectant cells were labeled with [ 35 S]methionine/cysteine (for 90 min), solubilized in 1% digitonin or 1% Nonidet P-40 detergent lysis buffer, immunoprecipitated with anti-TCR/ CD3 mAb and protein G-Sepharose beads, and analyzed by SDS-PAGE as described previously (27, 30, 31) .
Results
Induction of protective immunity against L12R4 cells
Injection of live T lymphoma cells like L12R4 or C6VL cells (100 -1000/mouse) kill C57BL/6 mice (B6) in 3-4 wk. In contrast, as many as 50 ϫ 10 6 L12R4 cells grow only transiently in BALB/c mice, which totally reject the tumor cells around day 10 (data not shown; Ref. 25) . However, if syngeneic mice are preimmunized with Mito-C-treated lymphoma cells, they become resistant to the tumor cells used for vaccination (23) (24) (25) . To get more insight into the mechanism of induction of the protective immune response, B6 mice were immunized with different doses of L12R4 M cells as described in Materials and Methods. Three weeks after the last vaccination, the mice were challenged with 10 3 live L12R4 cells. As can be seen in To demonstrate whether the increased proliferative and protective responses were attributable to increased frequency of L12R4-specific CD4
ϩ T cells and/or of APC-expressing L12R4 Ag in association with MHC class II molecules, we purified CD4 ϩ T cells from vaccinated mice. Such T cells alone do not respond to L12R4 M cells (Fig. 1B) . However, if normal, Mito-C-treated splenic APC were added to the cultures, the CD4 ϩ T cells proliferated in a manner similar to immune spleen cells (Fig. 1B) . Thus, the activity of L12R4-specific CD4 ϩ T cells elevates with increasing doses of vaccination. 
On the specificity of the protective immune responses to T lymphoma cells
Since both L12R4 and C6VL cells were of B6 origin but with different TCR␣␤ heterodimers (15, 25), one possible target Ag for the protective immunity was the TCR␣␤ variable regions. To get more direct evidence for a V␣/V␤-specific immunity, we induced mutagenesis in L12R4 cells (27) and isolated variant cells with no TCR/CD3 expression at the cell surface (FACS analysis with anti-CD3⑀ mAb). One resulting clone, P3.3, was used for subsequent experiments ( Fig. 2A) . [ 35 S]Methionine/cysteine-labeled TCR/ CD3 proteins were isolated from digitonin cell lysates by precipitation with anti-TCR.C␣, anti-TCR.C␤, or anti-CD3⑀ mAb. Precipitated material was separated by SDS-PAGE under reducing conditions. As can be seen in Fig. 2B , surface membrane TCR/ CD3-negative P3.3 variants (lanes 3) lacked expression of TCR␤ chains, whereas TCR␣ chains and CD3 molecules were present in the variant cells. P3.3 cells transfected with unrelated TCR-V␤2 cDNA regained surface expression of TCR-CD3 complexes (T142 cells, Fig. 2A ), indicating that the lack of TCR/CD3 membrane expression is due to the absence of autologous TCR␤ chains only. TCR-V␣ and TCR-V␤ cDNA from L12R4 cells were cloned and sequenced: L12R4 cells express V␣10 and V␤12J␤2.3 variable regions. We confirmed that P3.3 cells indeed lacked autologous TCR␤ chains by biosynthetic labeling and immunoprecipitation with anti-V␤12 mAb, and we could find no TCR␤ mRNA in P3.3 cells using PCR (data not shown). Transfection of P3.3 cells with V␤12 cDNA also reconstituted surface TCR/CD3 membrane expression (data not shown). Thus, a useful model system for the study of TCR␤-specific immunity was produced: V␣10 ϩ /V␤12 
ϩ T142 cells. Next, we immunized B6 mice with either Mito-C-treated L12R4 or P3.3 cells. The L12R4-primed mice were divided into three subgroups challenged with lethal doses of L12R4, P3.3, or T142 cells. Development of tumors was monitored every second day. The data in Fig. 3 show that L12R4-vaccinated mice were resistant to live L12R4 cells but not to P3.3 or T142 cells. In contrast, P3.3-vaccinated mice, compared with normal B6 mice, were only partially protected against live P3.3 cells (Fig. 3) . Furthermore, B6 mice vaccinated with T142 cells (V␤2 ϩ ) induced protective immunity to T142 cells but not to L12R4 or P3.3 cells (data not shown). These results and those from five independent experiments (24) suggest that V␤12 epitopes play an important role in the protective immunity to L12R4 cells. Moreover, antisera were isolated from vaccinated mice on the day of live tumor cell challenge and again 4 wk later when the tumor cells were rejected. Abs reactive against L12R4 cells but not against P3.3 cells were looked for using flow cytometry, but were not found (data not shown).
Characterization of the L12R4-specific effector cells
Immune cells in a protective tumor-immune response in vivo can inhibit proliferation of the same tumor cells in vitro (32) . Since we were unable previously to demonstrate V␤8.2-specific CTLs with reactivity in a standard 51 Cr release assay (23), we established a growth inhibition assay with L12R4 cells. L12R4 (10 4 ) cells were cultured for 1, 2, or 3 days and proliferation was measured by uptake of MTT dye. As negative control effector cells, we used normal spleen cells and BALB/c anti-B6 immune cells served as positive controls. Effector spleen cells from mice protected against L12R4 cells inhibited L12R4 cell growth, whereas P3.3 cell proliferation was affected much less (data not shown). Growth inhibition could be due to either induction of cell death or inhibition of one or more stages in the cell growth cycle induced by cytokines. Therefore, we cultured L12R4 cells with either normal spleen cells, L12R4-immune spleen cells, or BALB/c anti-L12R4 immune cells. The number of live V␤12 ϩ L12R4 cells was measured on days 1, 2, or 3 by flow cytometry. Seventy, 95, and 100% of V␤12 ϩ L12R4 cells were eliminated by L12R4-immune cells on (Fig. 4) . These data strongly suggest that L12R4 cell proliferation is arrested due to induction of cell death. Consequently, we tried to test the cytotoxic activity of either BALB/c anti-L12R4 T cells or L12R4-immune T cells from protected mice in a 51 Cr release assay. However, only allogeneic CTLs kill L12R4 cells efficiently in 4 -6 h; some specific cytotoxicity was observed with L12R4-immune T cells but only after 18 h, where the spontaneous 51 Cr release from L12R4 cells was ϳ40 -50% (data not shown). Thus, it appears that our effector T cells may be long-term killer cells (see Discussion).
To better characterize the effector cells, we made T cell lines from L12R4-immune spleen cells. The cell lines contained almost exclusively T cells on day 10. Tumor cell growth inhibitory activity increased during T cell culture, in particular if the cell line was supplemented with IL-2 during stimulation; in parallel, the proportion of CD8 ϩ T cells increased from ϳ30% to almost 100%. The data in Fig. 5 clearly demonstrate that the effector cells in the L12R4 growth inhibition assay were CD8 ϩ T cells and that they reacted autonomously. Furthermore, the CD8 ϩ T cells inhibited the growth of L12R4 cells, but not (or much less) the growth of P3.3, T142, or L1210 (H-2 d lymphoma cells). The results in Fig.  6 show that the CD8 ϩ T cells produced high amounts of IFN-␥ and TNF-␣ only when stimulated with L12R4 cells; they never produced detectable levels of IL-4 (or IL-2, data not shown).
L12R4-specific CD8 ϩ T cells transfer the protective state to naive recipients
Previously, we have shown that T cells from L12R4-protected mice could transfer protection to naive recipient mice (24) . In the present study, we asked whether CD8 ϩ T cells could transfer protection alone or whether CD4 ϩ T cells were also needed for effective protective immunity (Fig. 1) . The results in Fig. 7 demonstrate that L12R4-specific CD8 ϩ T cells from either L12R4-immune mice, or from L12R4-specific T cell lines, transferred complete immunity toward live L12R4 cells (but not to P3.3 cells, data not shown). Thus, V␤12-specific CD8 ϩ T cells appear to be the actual effector cells in passive transfer of protective immunity to L12R4 cells in vivo as well as in inhibition of L12R4 growth in vitro. 
Role of IFN-␥ in the protective immunity
IFN-␥ production by the V␤12-specific, CD8
ϩ T cells appears to be an important part of the effector function of these cells. Therefore, we investigated whether protective immunity against L12R4 cells could be induced in B6 mice lacking functional IFN-␥ genes. Normal and IFN-␥ Ϫ/Ϫ B6 mice were immunized three times with L12R4 M cells. After 2 wk, the mice were challenged with 10 3 live L12R4 cells. As before, almost 100% of normal B6 mice were protected by vaccination, whereas none of the IFN-␥ Ϫ/Ϫ B6 mice was protected by vaccination (data not shown). We then isolated T cells from the L12R4-immune mice and transferred these T cells to naive B6 mice of either normal or IFN-␥ Ϫ/Ϫ genotype. The data in Fig. 8 clearly show that L12R4-immune T cells from primed B6 mice can transfer protective immunity to both normal and IFN-␥ Ϫ/Ϫ B6 mice, although this protection is less long-lasting in IFN Ϫ/Ϫ mice. These results suggest that IFN-␥ production is necessary for L12R4-specific CD8 ϩ T cells to exert their protective activity against tumor cell growth (see Discussion).
On the fine specificity of the V␤12-reactive CD8
ϩ T cells
The peptide-binding motifs of H-2K b and H-2D b molecules are known (33) . Therefore, we asked whether the V␤12J␤2.3 sequence contained peptides with binding capacity to H-2 b class I molecules. The binding avidity of peptides to MHC class I molecules is directly proportional to the efficiency of peptide immunization in different model systems including vaccination against carcinomas (29, 34) . It was found that one V␤12 peptide, p70 -78, binds well to K b molecules (score ϳ24), whereas three V␤12 peptides may interact with D b molecules (p26 -34, p67-76, and p94 -102 with scores of 15, 14 and 19, respectively (33) ( Table I) . We concentrated our studies on a peptide, p67-78, that binds to both K b and D b molecules. This peptide induces a partially protective immune response to L12R4 cells, but not to T142 cells (Fig. 9) . These results are in accordance with the observation that p67-78 peptide has no significant homology to the equivalent V␤2 sequence (Table I) . The effector cells in p67-78 immune, L12R4-protected B6 mice were CD8 ϩ T cells with specificity for the p67-78 peptide. Such p67-78 peptide-reactive CD8 ϩ T cells transferred specific protection to naive B6 mice (Fig. 10) . CD8 ϩ T cell lines were produced from spleen cells of p67-78 peptide-vaccinated and L12R4-protected mice. Such cell lines inhibit L12R4 cell growth in vitro and this growth inhibition is almost abolished by the addition of anti-K b , anti-D b , or anti-H-2 mAb to the cultures (Fig. 11) . Anti-IA b mAb had no effect. Two more vaccination experiments were conducted, one in which the mice were immunized with 10, 30, 100, or 300 g of p67-78 peptide/CFA and another where the mice were immunized with 100 g of either p67-76 or p70 -78 peptide in CFA. In both experiments, 40 -60% of the mice were protected against L12R4 tumor cell growth, and there was no difference among groups of mice immunized with a different type or dose of V␤12 peptide (data not shown).
Thus, our results demonstrate that three V␤12 peptides that bind to K b or D b molecules are capable of inducing protective immunity to L12R4 cells.
Discussion
Syngeneic tumor-specific immune effector cells can be directed against overexpressed self-Ags; cryptic self Ags; mutated cell cycle control/signal transduction proteins; and, in the case of virally induced tumors, various viral peptides (35, 36) . Negative selection processes in the thymus normally eliminate self-reactive T cells (5, 6) . However, in some circumstances self-reactive T cells (e.g., TCR-V␤-reactive T cells) may emigrate from the thymus because of insufficient interactions between APC and T cells. In the present study, we used syngeneic T lymphoma cells to obtain more information about the nature and specificity of self-reactive TCR-specific T cells. T lymphoma cells present only a single TCR␣␤ heterodimer at the cell surface, and epitopes on these TCR␣␤ molecules could serve as a form of tumor-specific Ag(s) (15, 23, 24, 37, 38).
L12R4 T lymphoma cells express a V␣10/V␤12 TCR heterodimer and no other TCR␣ or TCR␤ sequences have been identified. A Table I ) restores TCR/CD3 surface membrane expression (T142 cells). Transfection of P3.3 with V␤12.C␤ cDNA also reconstitutes TCR/CD3 surface expression, thus strongly suggesting that the lack of TCR␤ chain expression is the only defect in P3.3 cells related to TCR/CD3 expression (Fig. 2) .
Vaccination of B6 mice with Mito-C-treated L12R4 cells induces specific protection, i.e., vaccinated mice reject L12R4 cells but not syngeneic C6VL (V␣9/V␤19) cells (see Refs. 15 and 24), P3.3 cells, or T142 cells (Fig. 3) . Vaccination against T142 cells induces protection against T142 cells and not against L12R4 cells (data not shown), whereas vaccination against P3.3 induces partial protection against P3.3, L12R4, and T142 cells but not C6VL cells (Fig. 4 and data not shown) . Thus, TCR-V␤12-specific immunity plays an important role in protection against L12R4 cells, though other self-tumor Ags may also be involved. Although protective immunity correlated with the proliferative activity of L12R4-reactive CD4 ϩ T cells, the effector cells in the protective immune response are CD8 ϩ V␤12-reactive T cells. These cells have cytotoxic activity (Figs. 4 and 5 ) and they produce IFN-␥ and TNF-␣ but not IL-4 (Fig. 6) . The production of IFN-␥ appears crucial for protection (38, 39) Thus, it appears that CD8 ϩ V␤12-reactive T cells play a major role in the protective immune response against L12R4 cells. Studies similar to ours have indicated that CD8 ϩ , V␤-specific T cells may be possible effector cells in T lymphoma cell rejection, but T lymphoma-specific Abs of the IgG2c isotype also play a significant role in normal as well as in IFN-␥ Ϫ/Ϫ B6 mice (38) . As mentioned in Results, we find no evidence for specific anti-L12R4 Abs (data not shown). The antisera from the present study are being analyzed for content of anti-TCR peptide Abs (12). (29, 34) (Fig. 9) . Immune CD8 ϩ T cells from the protected mice transfer complete protection to naive mice, suggesting that once established, V␤12 peptide-specific immunity confers efficient protection (Fig. 10) . L12R4-reactive CD8 ϩ T cell lines derived from p67-78 immune mice can be propagated in vitro with peptide and IL-2, and the L12R4-specific growth inhibition is abolished by Abs to K b or D b molecules (Fig. 11) . In addition, such T cells can convey L12R4-specific immunity autonomously in vivo (R. Llobera and B. Rubin, unpublished data). Thus, V␤12 peptide-specific CD8 ϩ T cells restricted to either K b or D b MHC class I molecules are responsible for a major part of the TCR␤-specific growth inhibition of L12R4 tumor cells. Future studies may investigate whether alternative D bbinding V␤12 peptides as well as V␣10 octamer peptides binding to K b or V␣10 nonamer/decamer peptides binding to D b may induce protective immunity. It is interesting to note that in four independent studies with different H-2 haplotypes and TCR-V␤ regions, a V␤ peptide around p65-80 shows immunogenicity and capacity to induce tumor rejection (Figs. 9 and 10 ) or down-regulation of autoimmunity, i.e., EAE (16, 21, 23) .
There is as yet no direct evidence for the association of V␤12 peptides with K b or D b molecules at the L12R4 cell surface (24) . This could be obtained by peptide elution from L12R4 and HPLC analysis (33) . However, immunization with p67-78/CFA induces protection against L12R4 cells, but not against T142 cells, and the protective immunity is mediated by CD8 ϩ T cells and not anti-TCR Abs. The only known difference between L12R4 and T142 cells is the expression of V␤12 and V␤2, respectively, and these two V␤ families show low homology, in particular in the p67-78 region (Table I) . Other indirect arguments come from studies on T cell biosynthesis. Only 1-5% of TCR␣␤ heterodimers reach the cell surface. Ninety-five percent or more of these molecules are degraded in a proteasome-dependent process (24, 31) . Consequently, TCR␣␤ peptides may be available for the MHC class I biosynthetic pathway (17) , and thus may be present on the T cell surface in association with MHC class I molecules. It is interesting to note that non-specific pathogen-free mice are more easily protected against L12R4 cells upon vaccination compared with specific pathogen-free mice. Thus, a certain "background" immunity may help to mount immune responses to tumor Ags. Such background immunity may consist of natural Abs and/or self-reactive T cells with specificity for TCR structures or peptides (12) .
An open question concerns the mechanism by which the CD8 ϩ V␤-specific T cells kill/eliminate their target cells. On one hand, TCR peptide-specific CTLs have been clearly demonstrated in vitro but the in vivo function of such cells was not assessed (14) . In contrast, CD8 ϩ TCR-specific T cells with in vivo function have been described previously (21) (22) (23) (24) . However, these killer cells do not lyse TCR peptide-expressing target cells in short-term lytic assays in vitro. This could be due to the absence of sufficient quantities of TCR peptide-MHC complexes on the target cell surface and/or to the mechanism of lysis used by the different CD8 ϩ T killer cells. The former possibility is supported by the studies of Reimann and colleagues (14) : TCR-peptide-loaded A20 target cells were killed by and could restimulate TCR peptide-specific CTL lines, whereas the same target cells transfected with relevant TCR␤ cDNA (and producing high levels of intracellular TCR␤ chains) were poorly lysed and they could not restimulate TCR peptide-specific CTL lines. The latter idea is supported by Ratner and Clark (40) , who found that short-term "acute" lysis is mainly mediated by perforin/granzyme mechanisms, whereas long-term "slow" lysis may be due to membrane-bound TNF-␣ on the CTLs.
In conclusion, we have described TCR peptide-specific, MHC class I-restricted CD8 ϩ T cells which play an important role in syngeneic T lymphoma cell rejection. Such T cells resemble TCRspecific CD8 ϩ T cells in autoimmune models of EAE (16, (21) (22) (23) . Although almost certainly CD8 ϩ T cells recognize V␤ peptide-MHC class I complexes on target L12R4 cells during in vitro and in vivo effector functions, it remains to be shown whether they gain sensitization to V␤ peptide/MHC on L12R4 cells (and other T lymphoma cells) or on some other APC. Given the stringent requirements for CD8 activation, the latter seems more likely.
